Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
30/11/2023 12:19
Nov 30 (Reuters) - Orchard Therapeutics PLC OT10y.F :
* ORCHARD THERAPEUTICS RECEIVES U.S. FDA FAST TRACK
DESIGNATION
FOR OTL-203 IN MPS-IH
* ORCHARD THERAPEUTICS PLC - GLOBAL REGISTRATIONAL TRIAL
EXPECTED
TO COMMENCE BY YEAR-END
* ORCHARD THERAPEUTICS - THROUGHOUT POC STUDY, TREATMENT
WITH
OTL-203 GENERALLY WELL-TOLERATED, SAFETY PROFILE CONSISTENT WITH
SELECTED CONDITIONING REGIMEN
Source text for Eikon: ID:nGNXcbQNfn
Further company coverage: OT10y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln